IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Carcinoma; Giant cell tumours; Squamous cell cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms IMPAACT
- 02 Oct 2023 Planned End Date changed from 1 Oct 2023 to 1 Dec 2024.
- 02 Oct 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Dec 2024.
- 06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology